An innovative new spray, the first of its kind, has been made available on prescription for the treatment of chronic wounds across the UK from this week.
The haemoglobin spray, marketed as Granulox, has been added to the NHS Drug Tariff, establishing a new Haemoglobin category.
As reported last year by Nursing Times, the novel treatment that involves oxygen therapy has show promise in a small study of UK patients with non-healing diabetic foot ulceration.
The company behind the product infirst Healthcare said the spray should be applied every time a dressing is changed, or at least every three days.
The bag-on-valve technology also means that Granulox can be sprayed at any angle, even upside down, for difficult to reach wound areas, it noted.
It said Granulox worked by increasing levels of oxygen at the wound bed, speeding up the rate of healing in wounds such as venous leg ulcers, by 75% compared to standard care. The treatment also reduces pain by an average of 68% within two weeks, it added.
“Patients can even administer the treatment themselves with support”
Studies have shown that, when added to standard care, Granulox could save an average of £2,330 for every diabetic foot ulcer patient and £1,469 for chronic wound patients after six months, it said.
Sharon Bateman, lead advanced nurse practitioner at Wellway Medical Group, a private GP-run service in Northumberland, has been administering Granulox with her patients.
She said: “The impact of chronic wounds is not only physical, but social and emotional too. Patients need to know that innovations like this are available to them.
“Granulox helps wounds to heal, reducing pain, time spent with nurses, and patients can even administer the treatment themselves with support, regaining confidence and independence,” said Ms Bateman, who trialed the product while in her previous post at South Tees Hospitals NHS Foundation Trust.
Alistair Copley, wound care manager at infirst Healthcare, added that the product joining the tariff was “good news for both patients and healthcare professionals”.
“We are pleased that Granulox has received this recognition and expect to see it being administered across the UK over the coming months,” he said.